RE:5 quarterI hear ya, I've got a large holding here as well.
The clinical results put forward thus far have been excellent, whereas following through on promises has been terrible. I'm a believer that PL has to be very careful in the type of deal he signs on as they are dilutive in nature as well. One thing that the analysts focused on with the last financing with Thomvest was that the warrants were dilutive, well once you give away a % of revs from a certain partnered indication you can't get that back. On the other hand providing this biotech gets up off the ground and starts generating the type of money PL has alluded to, share buybacks would then be an option to reduce the dilution we've exerienced of late.
Garth